Fortress Biotech logo
Fortress Biotech
FBIOP | NASDAQ
Chart Builder DCF Calculator
$13.86
-$0.50 (-3.48%)
At close: Nov 16, 2026, 4:00 PM ET
$13.86
$0.00 (-0.04%)
After-hours: Nov 16, 2026, 4:10 PM ET

Fortress Biotech Company Profile

Company profile explained

Company Profile

Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-nodular moderate to severe acne vulgaris; Zilxi for inflammatory lesions of rosacea; Exelderm, an antifungal cream and solution for topical use; Targadox, an oral doxycycline drug for therapy for severe acne; and Luxamend, a water-based emulsion to provide a moist healing environment for superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, sunburns, and radiation dermatitis. It also develops intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for Menkes disease; UNLOXCYT for metastatic cutaneous squamous cell carcinoma; Olafertinib for EGFR mutation-positive NSCLC; CAEL-101, a monoclonal antibody for amyloid light chain amyloidosis; and Triplex, a cytomegalovirus vaccine. In addition, the company's early-stage product candidates include Dotinurad for gout; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma and anaplastic astrocytoma; MB-106 for B-cell non-hodgkin lymphoma; AJ201, an androgen receptor degradation enhancer; and BAER-101, a positive allosteric modulator. Further, its preclinical product candidates comprise AAV-ATP7A and AVTS-001 gene therapies; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

Key Executives

Name Position
Lindsay Allan Rosenwald Executive Chairman, President & Chief Executive Officer
David Jin Chief Financial Officer & Head of Corporate Development
Michael S. Weiss Executive Vice Chairman of Strategic Development & Director
Xiaoqin Lu Chief Strategy Officer

Latest SEC Filings

Date Type Title
Oct 29, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Oct 01, 2026 8-K Current Report
Oct 01, 2026 4 Filing
Sep 01, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Aug 13, 2026 10-Q Quarterly Report
Aug 13, 2026 8-K Current Report
Jun 24, 2026 4 Filing
Jun 23, 2026 8-K Current Report
May 15, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
May 14, 2026 10-Q Quarterly Report
View All SEC Filings ➞
Fortress Biotech
Fortress Biotech logo
Country United States
IPO Date Nov 14, 2017
Industry Biotechnology
Sector Healthcare
Employees 78
CEO Lindsay A. Rosenwald

Contact Details

1111 Kane Concourse Bay Harbor Islands, Florida 33154 United States

Stock Details

Ticker Symbol FBIOP
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001429260
CUSIP Number 34960Q208
ISIN Number US34960Q2084
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.